IA
PACB icon

Integrity Advisory’s Pacific Biosciences PACB Stock Holding History

Integrity Advisory’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$140K Sell
17,109
-15,977
-48% -$138K 0.13% 73
2022
Q3 		$192K Buy
33,086
+18,824
+132% +$108K 0.18% 70
2022
Q2 		$63K Buy
14,262
+2,991
+27% +$18.2K 0.06% 69
2022
Q1 		$103K Buy
+11,271
New +$130K 0.1% 77

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Integrity Advisory's PACB Position: Q4 2022 in Review

Integrity Advisory reduced its Pacific Biosciences (PACB) stake by 48% in Q4 2022, selling an estimated $138K and leaving 17,109 shares worth $140K. The position accounts for 0.13% of the portfolio, ranked #73.

Integrity Advisory first reported a position in PACB in Q1 2022 and has held it in 4 quarters since. The position peaked at $192K in Q3 2022. 236 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

  • Integrity Advisory held 17,109 shares of Pacific Biosciences worth $140K as of Q4 2022.
  • Integrity Advisory sold 15,977 Pacific Biosciences shares in Q4 2022, an estimated $138K.
  • Pacific Biosciences made up 0.13% of Integrity Advisory's portfolio in Q4 2022, its #73 holding.
  • Integrity Advisory first reported a position in Pacific Biosciences in Q1 2022 and has held it in 4 quarters since.
  • Integrity Advisory's Pacific Biosciences position peaked at $192K in Q3 2022.
  • 236 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on Integrity Advisory's 13F filing for Q4 2022, filed 24 Jan 2023.